miRNA expression and function in thyroid carcinomas: a comparative and critical analysis and a model for other cancers

Manuel Saiselet _, Jaime M. Pita, Alice Augenlicht, Geneviève Dom, Maxime Tarabichi, Danai Fimereli, Jacques E. Dumont, Vincent Detours and Carine Maenhaut

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:52475-52492. https://doi.org/10.18632/oncotarget.9655

Metrics: PDF 2460 views  |   HTML 2875 views  |   ?  


Manuel Saiselet1, Jaime M. Pita1, Alice Augenlicht1, Geneviève Dom1, Maxime Tarabichi1, Danai Fimereli1, Jacques E. Dumont1, Vincent Detours1 and Carine Maenhaut1,2

1 Institute of Interdisciplinary Research (IRIBHM), University of Brussels, Brussels, Belgium

2 WELBIO, School of Medicine, University of Brussels, Brussels, Belgium

Correspondence to:

Jacques E. Dumont, email:

Manuel Saiselet, email:

Keywords: miRNA, cancer, function, expression profile, thyroid

Received: February 09, 2016 Accepted: May 16, 2016 Published: May 28, 2016


As in many cancer types, miRNA expression profiles and functions have become an important field of research on non-medullary thyroid carcinomas, the most common endocrine cancers. This could lead to the establishment of new diagnostic tests and new cancer therapies. However, different studies showed important variations in their research strategies and results. In addition, the action of miRNAs is poorly considered as a whole because of the use of underlying dogmatic truncated concepts. These lead to discrepancies and limits rarely considered. Recently, this field has been enlarged by new miRNA functional and expression studies. Moreover, studies using next generation sequencing give a new view of general miRNA differential expression profiles of papillary thyroid carcinoma. We analyzed in detail this literature from both physiological and differential expression points of view. Based on explicit examples, we reviewed the progresses but also the discrepancies and limits trying to provide a critical approach of where this literature may lead. We also provide recommendations for future studies. The conclusions of this systematic analysis could be extended to other cancer types.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9655